NEW YORK, June 20, 2016 /PRNewswire/ --
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
On Friday, shares in Cambridge, Massachusetts-based biopharma Company, Eleven Biotherapeutics Inc., ended the session 9.34% lower at $2.33 with a total volume of 2.29 million shares traded. The Company's shares have rallied 94.17% in the last one month and 494.39% in the previous three months. The stock is trading 98.72% above its 50-day moving average and 34.16% above its 200-day moving average. Moreover, shares of Eleven Biotherapeutics have a Relative Strength Index (RSI) of 63.88. Sign up and read the free notes on EBIO at:
On Friday, shares in Redwood City, California headquartered biopharma Company, Relypsa Inc., recorded a trading volume of 4.87 million shares, which was higher than their three months average volume of 3.00 million shares. The stock ended the day 4.33% lower at $17.90. The Company's shares have surged 24.65% in the last one month and 32.99% in the previous three months. The stock is trading above its 50-day moving average by 0.14%. Furthermore, shares of Relypsa have an RSI of 48.78. The complimentary notes on RLYP can be downloaded in PDF format at:
San Ramon, California-based biopharma Company, Galena Biopharma Inc.'s stock finished Friday's session 3.26% higher at $2.22 with a total volume of 4.74 million shares traded. Over the last one month and the previous three months, the Company's shares have rallied 50.00% and 152.27%, respectively. Additionally, the Company's stock has gained 23.33% in the past one year. The stock is trading above its 50-day and 200-day moving averages by 38.52% and 60.17%, respectively. Galena Biopharma's stock has an RSI of 71.34. Register for free on Stock-Callers.com and access the latest research on GALE at:
Thousand Oaks, California headquartered biotech Company, Amgen Inc.'s stock lost 1.76% to close the day at $149.62. The stock recorded a trading volume of 4.68 million shares, which was above its three months average volume of 2.81 million shares. The Company's shares have advanced 3.50% in the past three months. The stock is trading 1.37% below its 200-day moving average. Additionally, Amgen's stock traded at a PE ratio of 15.83 and has an RSI of 33.18. Get free access to your trade alert on AMGN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP Email: firstname.lastname@example.org Phone number: +44 330 808 3765 CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA